Page last updated: 2024-10-13

2-ethynylaniline

Description

2-ethynylaniline: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID4153905
CHEMBL ID394629
SCHEMBL ID170846
MeSH IDM0464877

Synonyms (25)

Synonym
2-ethynylaniline, 98%
2-ethynylaniline
CHEMBL394629
2-ethynylbenzenamine
AKOS005257064
2-ethynyl-phenylamine
52670-38-9
benzenamine, 2-ethynyl-
2-aminophenylacetylene
SCHEMBL170846
2-ethynyl aniline
ALQPJHSFIXARGX-UHFFFAOYSA-N
mfcd00168862
DTXSID30399999
J-508067
CS-W004892
STL554949
n-(2-chloromethyl)-n-methylpiperidine,hydrochloridesalt
AS-10515
AMY23137
BBL101153
SY066830
A847480
E1410
EN300-743880
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID728439Binding affinity to Enterobacteria phage T4 lysozyme L99A/M102H double mutant expressed in Escherichia coli BL21(DE3) assessed as change in melting temperature at 0.5 mM at pH 6.8 by circular dichroism analysis2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
The impact of introducing a histidine into an apolar cavity site on docking and ligand recognition.
AID299150Growth inhibition of Verticillium lamellicola at 50 ug/mL2007Bioorganic & medicinal chemistry letters, Apr-01, Volume: 17, Issue:7
Design and synthesis of beta-methoxyacrylate analogues via click chemistry and biological evaluations.
AID728440Binding affinity to Enterobacteria phage T4 lysozyme L99A/M102H double mutant expressed in Escherichia coli BL21(DE3) assessed as change in melting temperature at 0.5 mM at pH 5.4 by circular dichroism analysis2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
The impact of introducing a histidine into an apolar cavity site on docking and ligand recognition.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (16)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's7 (43.75)29.6817
2010's7 (43.75)24.3611
2020's2 (12.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other16 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]